Fidelity Investments
ATNM icon

Fidelity Investments’s Actinium Pharmaceuticals ATNM Stock Holding History

Fidelity Investments’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-79
Closed -$79 – 5575
2026
Q1 		$79 Sell
79
-14,294
-99% -$17K ﹤0.01% 5277
2025
Q4 		$19.5K Sell
14,373
-6,727
-32% -$9.81K ﹤0.01% 4471
2025
Q3 		$33.8K Sell
21,100
-3,217
-13% -$5.24K ﹤0.01% 4150
2025
Q2 		$34K Buy
24,317
+11,738
+93% +$17.6K ﹤0.01% 4076
2025
Q1 		$20.3K Buy
12,579
+7,839
+165% +$9.95K ﹤0.01% 4220
2024
Q4 		$5.97K Sell
4,740
-3,771
-44% -$5.85K ﹤0.01% 4625
2024
Q3 		$16K Buy
8,511
+2,610
+44% +$10.3K ﹤0.01% 4273
2024
Q2 		$43.7K Buy
5,901
+2,999
+103% +$24.7K ﹤0.01% 3685
2024
Q1 		$22.7K Sell
2,902
-26
-0.9% -$167 ﹤0.01% 3965
2023
Q4 		$14.9K Sell
2,928
-212
-7% -$1.09K ﹤0.01% 4088
2023
Q3 		$18.6K Buy
3,140
+2,860
+1,021% +$19K ﹤0.01% 3849
2023
Q2 		$2.08K Buy
280
+266
+1,900% +$2.26K ﹤0.01% 4584
2023
Q1 		$128 Buy
+14
New +$148 ﹤0.01% 4881
2020
Q3 		– Sell
-6
Closed – – 3660
2020
Q2 		$0 Hold
6
– – ﹤0.01% 3567
2020
Q1 		$0 Hold
6
– – ﹤0.01% 3606
2019
Q4 		$0 Buy
+6
New +$41 ﹤0.01% 3765

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's ATNM Position: Q2 2026 in Review

Fidelity Investments sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 79 shares — an estimated $79 sold.

Fidelity Investments first reported a position in ATNM in Q4 2019 and held it in 16 quarters. The position peaked at $43.7K in Q2 2024. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Fidelity Investments reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 79 Actinium Pharmaceuticals shares in Q2 2026, an estimated $79.
  • Fidelity Investments first reported a position in Actinium Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Fidelity Investments's Actinium Pharmaceuticals position peaked at $43.7K in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.